{"id":1989,"date":"2020-01-13T13:53:43","date_gmt":"2020-01-13T13:53:43","guid":{"rendered":"https:\/\/rhepa.se\/?p=1989"},"modified":"2020-03-25T10:34:52","modified_gmt":"2020-03-25T10:34:52","slug":"rhenman-healthcare-equity-l-s-decenniets-basta-lakemedelsfond","status":"publish","type":"post","link":"https:\/\/rhepa.se\/en\/rhenman-healthcare-equity-l-s-decenniets-basta-lakemedelsfond\/","title":{"rendered":"Rhenman Healthcare Equity L\/S &#8211; Decenniets b\u00e4sta l\u00e4kemedelsfond"},"content":{"rendered":"<p><b>&#8221;B\u00e4sta l\u00e4kemededelsfond<\/b>\u00a0\u00e4r hedgefonden\u00a0<b>Rhenman Healthcare Equity L\/S RC1 SEK<\/b>. Det \u00e4r\u00a0en l\u00e5ng\/kort aktiefond som investerar i h\u00e4lsov\u00e5rdsbolag p\u00e5 global basis. Fonden f\u00f6rvaltas av Henrik Rhenman sedan starten 2009. Avkastningen imponerar med 468 procent i avkastning.<\/p>\n<p><b>The fund\u00a0<\/b>har drygt 82 procent investerat i amerikanska h\u00e4lsov\u00e5rdsbolag och knappt 15 procent i europeiska. De st\u00f6rsta innehaven \u00e4r det amerikanska l\u00e4kemedelsbolaget Esperion Therapeutics med 4,7 procent. N\u00e4st st\u00f6rsta innehav \u00e4r amerikanska biofarmacibolaget Vertex Pharmaceuticals med bas i Boston p\u00e5 4,2 procent.&#8221;<\/p>\n<p>https:\/\/www.avanza.se\/placera\/redaktionellt\/2020\/01\/13\/decenniet-basta-fonder.html<\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>&#8221;B\u00e4sta l\u00e4kemededelsfond\u00a0\u00e4r hedgefonden\u00a0Rhenman Healthcare Equity L\/S RC1 SEK. Det \u00e4r\u00a0en l\u00e5ng\/kort aktiefond som investerar i h\u00e4lsov\u00e5rdsbolag p\u00e5 global basis. Fonden f\u00f6rvaltas av Henrik Rhenman sedan starten 2009. Avkastningen imponerar med 468 procent i avkastning. Fonden\u00a0har drygt 82 procent investerat i amerikanska h\u00e4lsov\u00e5rdsbolag och knappt 15 procent i europeiska. De st\u00f6rsta innehaven \u00e4r det amerikanska l\u00e4kemedelsbolaget [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1989","post","type-post","status-publish","format-standard","hentry","category-rhenman_partners"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/1989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/comments?post=1989"}],"version-history":[{"count":1,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/1989\/revisions"}],"predecessor-version":[{"id":1991,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/1989\/revisions\/1991"}],"wp:attachment":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/media?parent=1989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/categories?post=1989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/tags?post=1989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}